TrialNature communications2023

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial.

Chengzheng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.